LivingGLP1
Study S003316

A Single-dose, Open Design Study to Evaluate The Pharmacokinetics of HR17031 Injection With Renal Insufficiency

Registration

Registration
NCT05292495
Study type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Phase
PHASE1
Masking
NONE
Status
COMPLETED
Enrollment
24
Start
2022-10-12
Primary completion
2024-04-10
Lead sponsor
Jiangsu HengRui Medicine Co., Ltd.
Conditions
Improved Glycemic Control in Patients With Type 2 Diabetes
Interventions
DRUG:HR17031 injection
Results posted
FALSE
Individual participant data sharing
UNDECIDED

Registered primary outcomes

  • Pharmacokinetics parameters of INS068 and SHR20004: Cmax [Based on pre-dose, 2-96 hours post-dose sampling times]
  • Pharmacokinetics parameters of INS068 and SHR20004: AUC0-t [Based on pre-dose, 2-96 hours post-dose sampling times]
  • Pharmacokinetics parameters of INS068 and SHR20004: AUC0-inf [Based on pre-dose, 2-96 hours post-dose sampling times]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.